{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:47:53Z","timestamp":1785934073042,"version":"3.56.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ketamine has analgesic and sedative properties that are thought to reduce opioid tolerance and opioid-induced hyperalgesia. For this reason, ketamine may be used to manage pain and agitation, although the literature evaluating its use for this purpose is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the prescribing practices of ketamine in the medical intensive care unit (MICU) as it pertains to pain and agitation, as well as assess measures of safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a single-center, retrospective cohort study of critically ill patients who received a ketamine infusion for pain and\/or agitation between June 2021 and August 2024. The primary outcome was opioid consumption, reported in oral morphine milligram equivalents (MME), and sedative use pre- versus post-ketamine initiation. Secondary outcomes included paired mean pain scores, proportion of time within goal Richmond Agitation-Sedation Scale score range, and incidence of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      For the 78 patients included, there was no difference in analgesic use pre- versus post-ketamine initiation (60 vs 45 MME;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.677). No differences were observed in sedative doses required pre- versus post-ketamine initiation (5.3 vs 3.4 mg of benzodiazepines;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.508, 0.9 vs 1.1 \u03bcg\/kg\/h of dexmedetomidine;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.062, and 44 vs 44 \u03bcg\/kg\/min of propofol;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.180). There was a median paired difference of \u22121 point on the pain scale ([interquartile range \u22121, 0];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.030) after ketamine initiation. Ketamine was associated with an increased incidence of hallucinations (1.3% vs 6.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.046).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>To the authors\u2019 knowledge, this is the first study examining the use of ketamine for pain and\/or agitation that specifically focuses on MICU patients. The clinical benefit of the routine use of ketamine for these indications in this patient population is unclear and may increase patients\u2019 risk of adverse effects such as hallucinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251410532","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:37:14Z","timestamp":1768624634000},"page":"860-865","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of the Prescribing Practices of Ketamine for Pain and Agitation in the Medical Intensive Care Unit"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9985-8335","authenticated-orcid":false,"given":"Shaelyn","family":"Cooper","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The University of Vermont Medical Center, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryEllen","family":"Antkowiak","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Vermont Medical Center, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Devine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Nashett","family":"Wren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Vermont Medical Center, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000075837.67275.36"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2223"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2042"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066615620592"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066617706907"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31467-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.05.026"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06511-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2065"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0000000000002103"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000157"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000633"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2000.tb01076.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.05.016"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.12.004"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251410532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251410532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251410532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:07:37Z","timestamp":1785931657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251410532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/10600280251410532"],"URL":"https:\/\/doi.org\/10.1177\/10600280251410532","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}